SELLAS Life Sciences Granted FDA Rare Pediatric Disease Designation For SLS009 CDK9 Inhibitor For Treatment Of Pediatric Acute Lymphoblastic Leukemia; Eligible For Priority Review Voucher Worth Over $100M Upon Approval
Portfolio Pulse from Benzinga Newsdesk
SELLAS Life Sciences has been granted FDA Rare Pediatric Disease Designation for its SLS009 CDK9 inhibitor, aimed at treating pediatric acute lymphoblastic leukemia. This designation makes the company eligible for a Priority Review Voucher worth over $100 million upon approval.
June 24, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SELLAS Life Sciences has received FDA Rare Pediatric Disease Designation for its SLS009 CDK9 inhibitor, which targets pediatric acute lymphoblastic leukemia. This designation could lead to a Priority Review Voucher worth over $100 million upon approval.
The FDA Rare Pediatric Disease Designation is a significant milestone for SELLAS Life Sciences, as it not only validates the potential of SLS009 but also makes the company eligible for a Priority Review Voucher worth over $100 million upon approval. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100